$ENTA News

ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) Q2 Results: Narrower Losses, Clinical Milestones in Focus

Enanta Pharma Q2 EPS $(0.45) Beats $(0.49) Estimate, Sales $17.159M Beat $17.092M Estimate

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

Enanta Pharmaceuticals To Highlight Pipeline Progress With Oral Presentation And Asthma Drug Posters

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria

Enanta Pharmaceuticals Announced That The First Participant Has Been Dosed In A Phase 1 Clinical Trial Of EDP-978, An Oral, Once-daily Kit Inhibitor In Development For Urticaria And Other Mast Cell-driven Diseases

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026

Enanta Pharmaceuticals To Present Phase 2 Data For Zelicapavir In RSV Showing Faster Symptom Resolution And Lower Hospitalization At ESCMID Global 2026

Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)

Enanta Pharma To Present Data For STAT6 Inhibitor Program At IMMUNOLOGY2026TM, Annual Meeting Of AAI

Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference

Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference

What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock

Enanta Pharmaceuticals Announces $150M Offering

Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting

Enanta Pharmaceuticals To Showcase Preclinical Data For EDP-978, A Potential Treatment For Mast Cell-Mediated Type 2 Immune Diseases At AAAAI 2026

HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $20 Price Target

Enanta Pharmaceuticals (NASDAQ:ENTA) Beats Q1 Estimates, Reaffirms Cash Runway Into 2029